Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences rSU rollforward — Nonvested shares at period-end (M shares)
Form 10-K Note 13 Stock-Based Compensation
Latest, FY2025
18
Period ended Dec 31, 2025
Change on a year earlier
-18.3%
22 in FY2024
History
10 years
Since FY2014
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | RSU rollforward — Nonvested shares at period-end (M shares) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18 | -18.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 22 | -4.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 23 | -3.8% | Form 10-K (filed 2025-02-28) ↗ |
| FY2022 | Dec 31, 2022 | 24 | +12.9% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 21 | +7.2% | Form 10-K (filed 2023-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 20 | +13.4% | Form 10-K (filed 2022-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 17 | +15.5% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 15 | -0.8% | Form 10-K (filed 2019-02-26) ↗ |
| FY2017 | Dec 31, 2017 | 15 | – | Form 10-K (filed 2019-02-26) ↗ |
| FY2014 | Dec 31, 2014 | 14 | – | Form 10-K (filed 2015-02-25) ↗ |
Breakdown
What makes up rsu rollforward — nonvested shares at period-end (m shares)
Cite this data
StockData. (2026). Gilead Sciences RSU rollforward — Nonvested shares at period-end (M shares), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rsu_nonvested_sh
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.